Sarcopenia — age-related muscle mass and strength loss — results from declining GH/IGF-1 axis, reduced satellite cell activity, chronic low-grade inflammation, mitochondrial dysfunction in muscle fibers, and impaired neuromuscular signaling. Peptide research targets the anabolic signaling deficit and inflammatory environment that makes sarcopenia self-perpetuating.
1. IGF-1 LR3 — Direct Muscle Anabolic Signal
IGF-1 LR3 is the most potent direct anabolic signal for skeletal muscle. It activates satellite cells (muscle stem cells), promotes muscle fiber hypertrophy via PI3K/Akt/mTOR signaling, and counteracts the catabolic effects of inflammatory cytokines that drive sarcopenic muscle breakdown. Its extended half-life provides sustained anabolic drive unlike native IGF-1.
Dosing Protocol: 20–50 mcg SubQ or IM post-resistance training. Cycle strictly: 4 weeks on, 4–6 weeks off. Monitor blood glucose.
2. Ipamorelin + CJC-1295 — GH Axis Restoration
Age-related GH decline (somatopause) is the primary driver of sarcopenia. Ipamorelin/CJC restores physiological GH pulsatility, which drives IGF-1 production, promotes muscle protein synthesis, reduces visceral fat that promotes muscle catabolism, and improves sleep quality — the period of maximum muscle repair.
Dosing Protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295 SubQ before bed. 5 on/2 off. Cycle: 16–24 weeks for sarcopenia.
3. BPC-157 — Anti-Catabolic / Muscle Repair
Inflammatory cytokines (IL-6, TNF-α) drive muscle protein catabolism in sarcopenia. BPC-157 suppresses this inflammatory muscle breakdown while promoting satellite cell activation for new fiber synthesis. It also reduces the fibrosis that replaces functional muscle tissue with connective tissue in aging muscle.
Dosing Protocol: 250–500 mcg SubQ daily. Cycle: 8–12 weeks.
4. MK-677 (Ibutamoren) — Oral GH Secretagogue
MK-677 is an oral ghrelin mimetic that significantly and consistently elevates GH and IGF-1 levels. Clinical trials in elderly subjects show meaningful improvements in muscle mass and function with MK-677 use. It provides a convenient oral option for sustained GH secretagogue support in sarcopenia protocols.
Dosing Protocol: 10–25 mg oral daily, taken before bed. Long-term use (6–12 months) studied with acceptable safety profiles in aging populations.
Ipamorelin/CJC and MK-677 restore the GH/IGF-1 axis that is the root hormonal cause of sarcopenia. IGF-1 LR3 provides the direct anabolic signal driving muscle fiber hypertrophy and satellite cell activation. BPC-157 suppresses the inflammatory muscle catabolism that counteracts every anabolic intervention — making it an essential anti-catabolic component of any sarcopenia protocol.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).